Remix will receive $30 million upfront and is eligible to receive up to $12 million in near-term milestone payments and up to $1 billion in milestone payments and royalties WATERTOWN, Mass., Jan. 3, ...

CAMBRIDGE, Mass., Dec. 8, 2020 /PRNewswire/ -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing to address the underlying drivers of ...

As the science of drug discovery has grown in scale and gotten more complicated, so have the drug molecules themselves. But there’s a promising class of drugs made of just a handful of atoms that ...

Few-molecule reservoir computing is an emerging paradigm in nanoscale information processing that harnesses the complex dynamics of small ensembles of molecules to perform computational tasks. By ...

Small molecule drugs dominate new drug approvals and are crucial for treating diverse diseases. They are typically low-weight, providing easy absorption and versatile delivery methods. Their simpler ...

A version of this story appeared in Volume 101, Issue 36 Not too long ago, these small-molecule drugs looked as if they were going out of fashion. Advances in biotechnology enabled pharmaceutical ...

The "Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Nov 19, 2025)" training has been added to ResearchAndMarkets.com's offering. An active pharmaceutical ingredient (API) or ...